Skip to content

The clinical efficacy of Quetiapine in the treatment of PD hallucinations and the mechanism of electrophysiology and brain imaging

The clinical efficacy of Quetiapine in the treatment of PD hallucinations and the mechanism of electrophysiology and brain imaging

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064086
Enrollment
Unknown
Registered
2022-09-26
Start date
2022-09-27
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease with hallucinations

Interventions

PD with visual hallucinations:Quetiapine
PD without visual hallucinations:none
healthy elderly people:none

Sponsors

Nanjing Brain Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria of Parkinson's disease established by the The Movement Disorder Society (MDS); 2. Having hallucinations within one month before enrollment; 3. Having normal cognitive ability and being able to complete a series of questionnaires completely and accurately; Able to identify basic objects and people; 4. To maintain good self-physical control, with a quiet physical state to complete the experiment.

Exclusion criteria

Exclusion criteria: 1. Suffering from eye diseases (i.e. diplopia, cataract, glaucoma, retinitis, Retinal detachment, diabetes or hypertensive ophthalmopathy); 2. Cerebral infarction; 3. Dementia with Lewy bodies; 4. According to the DSM-5 criteria, primary mental disorders, including schizophrenia and bipolar disorder, or taking psychotropic drugs; 5. Unable to walk independently (e.g. wheelchair); 6. Wearing metal implants such as artificial pacemaker, artificial valves, false teeth, contraceptive rings, etc. 7. Drug allergy patients.

Design outcomes

Primary

MeasureTime frame
electroencephalogram;Brain MRI;scale;

Countries

China

Contacts

Public ContactLiu Weiguo
liuweiguo1111@sina.com13914725569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026